Bridging Gaps in MS Progression: How to Reconcile Clinical, Imaging, and Biomarker Discordance

In this episode, the panel addresses challenges that arise when clinical symptoms, MRI findings, and laboratory biomarkers provide conflicting information in the management of multiple sclerosis. They describe real-world scenarios where a patient’s biomarker results, such as elevated GFAP, may warn of progression even when clinical exams and imaging remain stable. Panelists emphasize that, in these situations, clinical judgment and experience play a crucial role in deciding how much weight to assign to laboratory data versus patient history and imaging results. The group discusses difficulties in utilizing new biomarkers, including insurance coverage for advanced tests, the frequency of actionable results, and uncertainties in interpretation. They highlight the need for ongoing research to better understand and integrate these tools into practice, while reiterating that no single test should override a comprehensive, individualized patient assessment. The conversation reflects cautious optimism for future advancements.